ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has entered into a connected transaction through a loan agreement dated February 10, 2026. Under the agreement, the company will provide a loan of RMB13,724,673.60 to Dr. Tian Wenzhi, who serves as the executive Director, chief executive officer, chairman of the Board, and is a substantial shareholder of the company. The connected transaction falls under Chapter 14A of the Hong Kong Listing Rules and, as the relevant percentage ratios exceed 0.1% but are below 5%, it is subject to reporting and announcement requirements but is exempt from circular and independent shareholders' approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260210-12021100), on February 10, 2026, and is solely responsible for the information contained therein.